

## Close of IPO and Name Change to VGI Health Technology Limited

**Sydney New South Wales, 20 April 2021** – The Directors are pleased to announce that Azure Health Technology Limited's (**Company** or **AZT's**) Initial Public Offering (**IPO**) closed at 5:00pm on 16 April 2021. The IPO raised \$2,497,000 and the directors are pleased to welcome VGI Group as a cornerstone investor having invested \$2,250,000 in the Offer.

Dato Seri Dr. Vincent Lim Seng Peng, the Chairman of VGI Group said "We recognised from the start of our discussions with AZT that the Company has biotechnology assets which have enormous value and scope for growth. The patented nutraceutical products which will generate immediate revenues and the two Phase II-ready clinical development assets which are expected to have efficacy data readouts for NASH (Non-Alcoholic SteatoHepatitis) and Pancreatic Adenocarcinoma (pancreatic cancer) in the next two years makes AZT a very attractive investment for VGI. We are also impressed by the Management Team and Scientific Advisory Board which have a proven track record in the commercialisation of nutraceuticals and pharmaceuticals."

The Chairman of AZT, Mr Lou Panaccio, said "The directors would like to take this opportunity to welcome VGI Group our share register as a major strategic investor. This is testimony to the value of Azure's assets when a major corporate investor comes on board for an IPO. The proceeds of the IPO allow the launch of our nutraceutical products in the US and the advancement of our clinical development program for NASH and Pancreatic Adenocarcinoma."

In recognition of the importance of the VGI Group becoming a substantial shareholder in AZT, the Company will now trade as Azure Health Technology Limited trading as VGI Health Technology and upon the listing of its shares on the National Stock Exchange which is expected to be in the week commencing 26 April 2021, the ticker code will be NSX:VTL. Additionally, in the next couple of months, the Company will call an extraordinary general meeting of shareholders to change its name to VGI Health Technology Limited.

For more information please contact:

**Glenn Tong**, CEO and Managing Director

Ph: +61 (0) 412 193 350

**Catriona Glover**, Company Secretary

Tel: +61 (0) 402 328 200

**Andrew Crook**, Investor and Media Relations

Ph:+61 (0) 419 788 431

---

### **About Azure Health Technology Limited**

Azure Health Technology Limited (AZT) is an Australian public unlisted biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. AZT owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.

For more information see: <https://www.azureht.com.au>